Transaction · 0001193125-26-355493

Catinazzo Thomas

Catinazzo Thomas, CFO, reported an open-market or private sale at Relay Therapeutics, Inc. involving 17717.000000 shares for an estimated $349733.58. Reported holdings after the transaction were 140568.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
RLAYRelay Therapeutics, Inc.
Filing timeAug 18
Trade dateAug 14, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$20.61
Pre-filing
1mo ago -5.3%1w ago -4.1%1d ago -3.3%
Returns since
7d -0.7%30d -10.3%90d -10.3%180d -10.3%1y -10.3%

RLAY price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RLAY since 2026-08-18Filed 16 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-355493
Common Stock
Transaction date
Aug 14, 2026
Filed Aug 18, 2026, 08:16 PM · 4d delay
Shares
17.7k sh
$1.97k per share
Estimated value
-$34.9M
Computed from shares × price
Holdings after
140k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Sale 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

  2. F2

    This transaction was executed in multiple trades at prices ranging from $19.51 to $19.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to p…

  3. F3

    Includes 6,538 shares underlying restricted stock units.

Original filing · 0001193125-26-355493
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RLAY